0001326110-24-000069.txt : 20240612 0001326110-24-000069.hdr.sgml : 20240612 20240612163610 ACCESSION NUMBER: 0001326110-24-000069 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240612 DATE AS OF CHANGE: 20240612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunityBio, Inc. CENTRAL INDEX KEY: 0001326110 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 431979754 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37507 FILM NUMBER: 241038888 BUSINESS ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (844) 696-5235 MAIL ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: NantKwest, Inc. DATE OF NAME CHANGE: 20150713 FORMER COMPANY: FORMER CONFORMED NAME: Conkwest, Inc. DATE OF NAME CHANGE: 20140416 FORMER COMPANY: FORMER CONFORMED NAME: ZelleRx Corp DATE OF NAME CHANGE: 20050504 8-K 1 ibrx-20240611.htm 8-K ibrx-20240611
FALSE000132611000013261102024-06-112024-06-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 11, 2024
ImmunityBio, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3750743-1979754
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
3530 John Hopkins Court
San Diego, California 92121
(Address of principal executive offices, including zip code)
(844) 696-5235
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.0001 per shareIBRXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Section 5 – Corporate Governance and Management
Item 5.07    Submission of Matters to a Vote of Security Holders.
On June 11, 2024, ImmunityBio, Inc. held its Annual Meeting of Stockholders (the “Annual Meeting”). Of the 677,036,411 shares of our common stock, par value $0.0001 per share (“Common Stock”) outstanding as of April 17, 2024, 609,540,014 shares of Common Stock were represented, either by attending the Annual Meeting virtually or by proxy, constituting (i) a quorum under the company’s bylaws and (ii) approximately 90% of the outstanding shares of Common Stock entitled to vote. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.
1.Election of Nine Directors. The following nominees were re-elected by the holders of our Common Stock to serve as directors for a one year term expiring at the 2025 annual meeting of stockholders based on the following results of voting. Each director’s term continues until the election and qualification of his or her successor, or until his or her earlier retirement, resignation, disqualification, removal, or death.
NomineeVotes “For”Votes “Withheld”“Broker Non-Votes”
Patrick Soon-Shiong, M.D.556,206,3556,438,67746,894,982
Cheryl L. Cohen561,728,022917,01046,894,982
Richard Adcock561,327,0021,318,03046,894,982
Michael D. Blaszyk561,317,1641,327,86846,894,982
John Owen Brennan560,173,1702,471,86246,894,982
Wesley Clark560,587,8162,057,21646,894,982
Linda Maxwell, M.D.561,368,9931,276,03946,894,982
Christobel Selecky561,329,8411,315,19146,894,982
Barry J. Simon, M.D.559,237,6003,407,43246,894,982
2.Approval of Amendment to Increase the Number of Shares of Common Stock Authorized for Issuance under the ImmunityBio, Inc. 2015 Equity Incentive Plan. The amendment to increase the number of shares of Common Stock authorized for issuance under the company’s 2015 Equity Incentive Plan by 19,900,000 shares was approved by our stockholders based on the following results of voting:
Votes “For”Votes “Against”Abstentions“Broker Non-Votes”
547,258,25712,472,0682,914,70746,894,982
3.Advisory Vote to Approve Named Executive Officer Compensation, or Say-on-Pay. On an advisory, non-binding basis, the compensation of our named executive officers for the year ended December 31, 2023, as disclosed in our proxy statement filed with the Securities and Exchange Commission on April 29, 2024, was approved by our stockholders based on the following results of voting:
Votes “For”Votes “Against”Abstentions“Broker Non-Votes”
556,683,3662,530,8583,430,80846,894,982
4.Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified by our stockholders based on the following results of voting:
Votes “For”Votes “Against”Abstentions“Broker Non-Votes”
606,920,4372,216,896402,681—


Section 9 – Financial Statements and Exhibits
Item 9.01    Financial Statements and Exhibits.
(d)    Exhibits.
Exhibit No. Description
  104 Cover page interactive data file (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNITYBIO, INC.
Date: June 12, 2024
By:/s/ David C. Sachs
David C. Sachs
Chief Financial Officer

 EX-101.SCH 2 ibrx-20240611.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ibrx-20240611_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Security 12b Title Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation State Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre Commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 4 ibrx-20240611_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 11, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 11, 2024
Entity Registrant Name ImmunityBio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-37507
Entity Tax Identification Number 43-1979754
Entity Address, Address Line One 3530 John Hopkins Court
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (844)
Local Phone Number 696-5235
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol IBRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001326110
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.immunitybio.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ibrx-20240611.htm ibrx-20240611.xsd ibrx-20240611_lab.xml ibrx-20240611_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ibrx-20240611.htm": { "nsprefix": "ibrx", "nsuri": "http://www.immunitybio.com/20240611", "dts": { "inline": { "local": [ "ibrx-20240611.htm" ] }, "schema": { "local": [ "ibrx-20240611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ibrx-20240611_lab.xml" ] }, "presentationLink": { "local": [ "ibrx-20240611_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.immunitybio.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibrx-20240611.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibrx-20240611.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation State Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security 12b Title", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.immunitybio.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001326110-24-000069-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001326110-24-000069-xbrl.zip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ibrx-20240611_htm.xml IDEA: XBRL DOCUMENT 0001326110 2024-06-11 2024-06-11 false 0001326110 8-K 2024-06-11 ImmunityBio, Inc. DE 001-37507 43-1979754 3530 John Hopkins Court San Diego CA 92121 (844) 696-5235 false false false false Common Stock, par value $0.0001 per share IBRX NASDAQ false